1. Introduction {#sec1}
===============

Greenspace exposure typically brings with it exposure to components of nature, including biodiverse environmental microbiomes, phytoncides, negative air ions, sunlight, and the sights and sounds of nature itself. There is growing evidence of the benefits of exposure to greenspaces via these components for human health outcomes, including lower blood pressure, lower cortisol levels, improved diabetes, reduced all-cause mortality, and fewer adverse birth outcomes ([@bib152]). These benefits may be enhanced with exposure to more biodiverse greenspaces ([@bib1]), with several proposed mechanisms ([@bib81]). The impact of any type of greenspace exposure on pain, however, is under-investigated ([@bib152]).

Pain is defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" ([@bib61]). Painful conditions are among the leading causes of the global disease burden, with lower back pain, neck pain, 'other' musculoskeletal disorders, and migraines among the top 10 leading causes of years lived with disability ([@bib159]). Indeed, lower back pain is the leading cause of years lived with disability in 65% of the 195 countries and territories investigated in the 2017 Global Burden of Disease study ([@bib64]). This burden is likely to increase during and following the current coronavirus pandemic, because lockdowns and physical distancing has necessitated changes to healthcare services, including the closure of pain clinics ([@bib36]), and the postponement or cancelation of elective surgeries ([@bib21]; [@bib133]).

Chronic pain is considered a condition in its own right, not simply a symptom, and is defined as "pain that persists or recurs for longer than 3 months" ([@bib162]). The prevalence of chronic pain is high. For example, the estimated prevalence of chronic pain, when defined as pain persisting for 3 months or longer, in the United Kingdom is 43.5% ([@bib38]), and when defined as pain persisting for 6 months or longer the prevalence is estimated to be 15.4% in Australia ([@bib108]), 20.4% in the United States of America ([@bib30]), and 27.2% in France ([@bib24]). The prevalence of chronic pain is similar in low-middle income countries ([@bib63]). For those with chronic pain in the United Kingdom, 10.4--14.3% report being moderately to severely disabled by their pain ([@bib38]). To reduce this disease burden, safe, effective and timely management options for people with pain are required, both to reduce the risk of transitioning from acute to chronic pain, and also to reduce the prevalence and impact of chronic pain. While many existing interventions contribute to reducing the community burden of chronic pain, novel interventions that further help are sought-after, and this paper explores a possible new approach -- exposure to greenspace.

In this narrative review we probe the question -- can exposure to greenspace reduce the high global burden of pain? To answer this question, we first review the nature of pain, followed by an exploration of the possible mechanisms by which exposure to greenspace could lead to more positive outcomes. 'Greenspace' has been defined in various ways in the existing literature ([@bib146]). For the purposes of this review, we have followed a broad definition of 'greenspace' as any natural environment, including, but not limited to, parks, ovals, forests and gardens.

2. Pain mechanisms {#sec2}
==================

Pain is a psychoneuroimmunoendocrinological process with three main types (nociceptive, neuropathic, nocipathic/nociplastic/algopathic; see [Table 1](#tbl1){ref-type="table"} for descriptions), which can occur simultaneously in some people ([@bib49]). Pain processing occurs independent of pathology ([@bib124]); hence, in this review, we discuss pain as a general condition, rather than focusing on pain from specific diseases or injuries (e.g. musculoskeletal, cancer, migraine).Table 1Characteristics for the three main pain categories.Table 1Pain categoryCharacteristicsNociceptive painInvolves the stimulation of nociceptors (the peripheral nerve terminals that detect noxious stimuli, which may be mechanical, chemical or thermal) ([@bib49]; [@bib97])\
Includes inflammatory pain ([@bib97])\
Protective mechanism -- the body\'s 'first detection' system ([@bib49]; [@bib97])\
Activation of nociceptors does not necessarily result in pain ([@bib49])\
The relationship between nociceptor activity and the pain experience is not linear ([@bib49])Neuropathic painInvolves a lesion of the somatosensory nervous system ([@bib61]; [@bib79]; [@bib97])\
May result from trauma or disease ([@bib155]), or repetitive mechanical loading or inflammatory irritation of the peripheral nerves ([@bib49])Nocipathic/nociplastic/algopathic painAlso described as 'dysfunctional pain' ([@bib114])\
Occurs in the absence of tissue threat or damage, and without somatosensory nervous system lesions ([@bib79])\
Pain may occur through altered nociceptive pathway function, pathological changes of nociception, or central sensitisation ([@bib49]; [@bib79]), which occurs when the central nervous system nociceptors become hypersensitive ([@bib97])\
Thought to be the pain type associated with visceral pain disorders, fibromyalgia and Complex Region Pain Syndrome Type 1 ([@bib79])

Pain is not simply the result of damage, or even a sensory signal, but rather pain is a conscious event ([@bib49]). Pain is complex and varies widely between and within individuals, with a broad range of factors potentially playing a role, including neurophysiological, immunological, psychological, contextual, environmental, and social factors ([@bib19]; [@bib43]; [@bib151]; [@bib157]). There are also many psychosocial factors associated with pain and poorer pain outcomes (e.g. transitioning from acute to chronic pain), such as stress, poorer mental health and lack of social coherence/support (see [Box 1](#tbox1){ref-type="boxed-text"} ).Box 1Examples of psychosocial factors associated with pain outcomes.Stress ([@bib34]; [@bib66])Poorer mental health (e.g. anxiety, depression) ([@bib34]; [@bib57]; [@bib66]; [@bib95])Lack of social coherence ([@bib66]) and support ([@bib40]; [@bib66])Sleep problems ([@bib7]; [@bib48])Beliefs about pain ([@bib112]) and pain control ([@bib33])Poorer expectations regarding pain ([@bib57])Catastrophisation ([@bib40]; [@bib57])Kinesiophobia/ fear-avoidance beliefs ([@bib34]; [@bib57]; [@bib66]; [@bib112])Fear of surgery ([@bib40])Perceived self-helplessness ([@bib40])Poor self-resilience ([@bib40])Poor self-efficacy ([@bib40])Having non-adaptive pain thoughts ([@bib66])Alt-text: Box 1

The brain integrates information from various sources (e.g. sensory information, beliefs about pain ), and pain may or may not result. The modulation of pain is influenced by non-nociceptive sensory input ([@bib113]), affective and cognitive factors ([@bib19]), and contextual cues ([@bib113]). Pain modulation occurs through anatomical or functional neurological changes ([@bib49]), and/or through various processes of the peripheral and central nervous systems ([@bib19]).

There are several neural factors potentially involved in the experience of pain. These neural factors include the activation of nociceptors (that detect noxious stimuli ([@bib49]; [@bib97])), and the descending pathways (that influence pain at the dorsal horn of the spinal cord ([@bib47]; [@bib175])). Pain modulation may also be influenced by pro-inflammatory mediators, nerve growth factors, hormones (e.g. endorphins) and epigenetic modifications, and involves immune cells, mast cells, macrophages, and leukocytes ([@bib47]). The activity of these cells is driven by several compounds, including short chain fatty acids and gamma-aminobutyric acid (GABA) ([@bib47]). An awareness of the nature of pain is important for contextualising and interpreting the potential role of pain-reducing interventions. However, a further discussion regarding pain mechanisms is beyond the scope of this paper; interested readers are instead referred to other reviews for further information (e.g. [@bib19], [@bib49], [@bib40], and [@bib47]).

3. How is pain currently treated? {#sec3}
=================================

Given the complex nature of pain, interventions can target various factors. Particularly in the acute phase, pain management may target nociception, including any underlying inflammation. In this acute phase, strategies to prevent the transition from acute to chronic pain may also be implemented, targeting any of the risk factors ([Table 2](#tbl2){ref-type="table"} ). These factors may continue to be targeted in chronic pain management, although treatments aimed at reducing hypersensitivity may be added. Finally, surgical options may be considered to address underlying problems (e.g. joint replacement, spinal fusion, nerve decompression), as well as strategies to reduce hypersensitivity. Chronic pain treatment is typically multidisciplinary and may be provided by a range of health professionals including physiotherapists, psychologists, occupational therapists, dentists, podiatrists, general practitioners, pain physicians, neurologists, anaesthetists, and appropriate surgeons (e.g. neurosurgeons, orthopaedic surgeons).Table 2Potential treatments for pain.Table 2TargetExamples of treatmentsReduce nociception & inflammation•Analgesics ([@bib40]; [@bib121])•Anti-inflammatory medications ([@bib40]; [@bib121])•Joint and/or neural mobilisation ([@bib2]; [@bib28]; [@bib100])•Electrophysical agents ([@bib15]; [@bib53]; [@bib164])•Surgery to address underlying problem (e.g. joint replacement)•Rhizotomy ([@bib9]; [@bib165])•Nerve blocks ([@bib20])Improving the emotional & cognitive factors•Pain education ([@bib148])•Meditation/mindfulness ([@bib10]; [@bib119])•Cognitive behavioural therapy ([@bib8]; [@bib50])•Graded exposure ([@bib98])Reduce hypersensitivity•Antidepressants (to modulate the opioid system) ([@bib121])•Anticonvulsants (to increases gamma-aminobutyric acid levels in the brain) ([@bib40]; [@bib121])•Electrophysical agents ([@bib15]; [@bib53])

The treatment of chronic pain can be complex, resource intensive, and have varying levels of success. Novel treatments to reduce the risk of transition from acute to chronic pain and to treat chronic pain itself are both required. These treatments need to be accessible in a timely manner, acceptable to the patient, safe, and cost-effective. While existing strategies contribute to managing pain, new strategies to manage pain should be explored to reduce the global burden further. Recent work on greenspace may provide an appropriate option to help reduce the high global burden of pain, particularly chronic pain.

4. Could exposure to greenspace help reduce the pain burden? {#sec4}
============================================================

Greenspace exposure has been associated with a range of positive health outcomes, including conditions associated with pain (e.g. lower stress levels, and better mental health ([@bib152])), providing some indication that greenspace exposure may have a beneficial impact on pain. Despite this, the relationship between greenspace and pain outcomes or painful conditions (e.g. musculoskeletal disorders) have not been adequately investigated ([@bib152]).

To our knowledge, only two studies ([@bib60]; [@bib101]) have investigated the possible association between greenspace exposure and pain or musculoskeletal outcomes, with mixed findings. [@bib101] investigated the relationship between the percentage of greenspace in circles with 1 or 3 km radii around the participants\' places of residence, and health conditions reported in general practice notes in the 12 months prior. The health conditions targeted included musculoskeletal conditions such as neck/back complaints, severe back complaints, severe neck/back complaints, and severe elbow/wrist/hand complaints, osteoarthritis, and arthritis ([@bib101]). Of these musculoskeletal conditions, there was a significant negative association between the percentage of greenspace in the 1 km radius circle and the number of neck/back complaints, severe back complaints, severe neck/back complaints, severe elbow/wrist/hand complaints ([@bib101]). No such significant association was found for the 3 km radius ([@bib101]). The study is directly relevant to the question we are asking, because ache, pain, or discomfort are generally used as proxy-measures of musculoskeletal disorders ([@bib82]), indicating that these symptoms can be pathognomonic of musculoskeletal disorders and that people diagnosed with musculoskeletal conditions are therefore likely to have experienced pain. However, one of the limitations of this study was that the patients with the musculoskeletal complaints studied might not necessarily present with pain.

In the second relevant study, [@bib60] investigated the association between the degree of "vegetation cover greenness" and "land use greenness" within the participants\' residential 'circuit', and whether the participants reported pain and/or stiffness in their muscles/joints in the last four weeks in three or more (of six) body regions (although the body regions were not listed). No association between greenspace and pain for males was observed, but for females the prevalence of pain/stiffness was higher in those living in areas with more vegetation cover greenness and land use greenness ([@bib60]). This unexpected finding should be interpreted with caution given a number of limitations. Firstly, the outcome measures employed were not tested for validity and reliability, and secondly there was no differentiation between pain and stiffness.

In both studies ([@bib60]; [@bib101]), the use of residential proximity to greenspace does not necessarily provide an accurate measure of a resident\'s greenspace exposure, owing to individual differences in exposure to greenspace.

We do however have additional corroborative evidence suggesting that a relationship is likely, and that further research in the area is worthwhile. There is evidence for example that forest therapy ([@bib51]; [@bib69]), exercise in green areas ([@bib59]) (not to be confused with 'green prescriptions' that refer to written advice to a patient regarding physical activity made by a health professional ([@bib118])), and involvement in horticultural therapy ([@bib74]; [@bib156]) and conservation ([@bib110]) are associated with better pain outcomes. However, these studies have not been designed with appropriate controls to ascertain whether greenspace exposure itself led to the benefits or whether these benefits could be due to other aspects, such as physical activity and/or social interaction. Furthermore, all used lower level study designs ([@bib107]; [@bib123]) (e.g. observational studies), and some studies of forest therapy and green exercise actually also included interventions (e.g. walking/hiking ([@bib51]; [@bib59]; [@bib69]), being residential ([@bib51]; [@bib59]), music therapy ([@bib51])), which were not provided to the comparison groups. As it stands, there is therefore some suggestion that greenspace exposure may assist in pain management, however the evidence to date is insufficient to determine whether the benefits are due to greenspace exposure *per se*.

In the following sections, we explore the biological plausibility of greenspace exposure *per se* leading to an improvement in pain outcomes (see conceptual model in [Fig. 1](#fig1){ref-type="fig"} ). These sections refer to the particular components of nature that greenspace exposure may provide, and we separately discuss those that are specific to greenspace (e.g. environmental microbiota, phytoncides, sights and sounds of greenspace) from those that are not greenspace-specific but are facilitated by greenspace exposure (e.g. sunlight, social integration and cohesion ([@bib67]), and physical activity ([@bib72])). We detail how these greenspace components could be linked to pain outcomes via various ecophysiological linkage mechanisms, some mechanisms of which are known, but including others that are not. Not represented in the conceptual model are additional intrinsic linkages within the ecophysiological linkage mechanisms, such as the influence of gut microbiome on mental health ([@bib96]; [@bib154]; [@bib167]). These added layers of complexity and unknowns must remain as open questions and are not discussed further in our study.Fig. 1Conceptual model linking greenspace exposure to pain outcomes. Not shown are additional potential pathways joining different ecophysiological linkage mechanisms.Fig. 1

4.1. Environmental microbiomes {#sec4.1}
------------------------------

The 'old friends' hypothesis proposes that humans evolved alongside a diverse suite of environmental microbiota (collectively known as 'microbiomes'), and that co-evolved symbiotic relationships developed ([@bib131]). This co-evolution underpins our argument that exposure to greenspace (with its microbiome) may positively influence pain outcomes. It has recently been demonstrated that direct soil contact changes the human skin microbiome ([@bib44]), and that exposure to different environments (and their respective microbiomes) changes the human nasal and skin microbiome ([@bib83]). Importantly, the latter study was conducted indoors and is therefore not susceptible to some of the potential confounding exposures present outdoors (e.g. direct plant/soil/animal interactions, exposure to sunlight and phytoncides) that may also influence the human microbiome (as discussed below). The influence of the environmental microbiome on the human gut microbiome is not currently well understood ([@bib17]; [@bib145]), however animal studies indicate such an influence ([@bib17]), even via indirect exposure to soil via the aerobiome only ([@bib92]).

The microbiome-gut-brain axis refers to the bidirectional communication between the gut microbiome, the gut and the brain, and is mediated by neurotransmitters, bacterial metabolites, cytokines, hormones and neural communication ([@bib70]; [@bib105]). Interest in the microbiome-gut-brain axis has increased dramatically since 2009, with over 500 papers published on the topic in 2018 alone ([@bib176]). However, pain as an outcome has been relatively under-investigated, with studies predominantly focusing on visceral pain ([@bib47]; [@bib127]). The relationship between the human microbiome and pain outcomes has recently been comprehensively reviewed, hence we provide only a summary of the current evidence base, with interested readers referred to [@bib47] and [@bib127] for further detail.

Associations between the human microbiome and a range of painful conditions have been reported. These conditions include endometriosis ([@bib87]), fibromyalgia ([@bib103]), myalgic encephalomyelitis/chronic fatigue syndrome ([@bib115]), interstitial cystitis/bladder pain syndrome ([@bib120]), chronic prostatitis/chronic pelvic pain syndrome ([@bib138]), dermatitis ([@bib46]), and inflammatory bowel disease ([@bib77]). Furthermore, there is emerging experimental evidence that changing the gut microbiome through probiotics (*Lactobacillus casei* Shirota ([@bib86]), *L. gasseri* OLL2809 ([@bib62]), and combined *L. acidophilus, L. plantarum, L. fermentum* and *L. gasseri* ([@bib73])) reduces pain in people with knee osteoarthritis ([@bib86]), and endometriosis ([@bib62]; [@bib73]). Recently, faecal microbiota transplants have also been shown to reduce pain in those with fibromyalgia ([@bib150]) and *Clostridium difficile* infection ([@bib3]). Although these positive results could be due either to changes in the disease state or to changes in pain processing, they nonetheless suggest that exposure to greenspace -- and its associated environmental microbiomes -- may lead to reductions in pain, via changes in the human microbiome.

A recent study by [@bib137] reported an association between stool consistency (a proxy measure of the gut microbiome) and pain intensity (initiated by mechanical stimulation of the inter-digital space between the second and third, and the fourth and fifth digits of the right hand). This study provides some evidence of the potential role of gut microbiome in pain perception, although the causal mechanisms are still hypothetical.

As outlined above, the gut microbiome can influence the brain via various microbially-mediated mechanisms, and those related to chronic pain have recently been reviewed elsewhere ([@bib47]). Microbiota-derived mediators may decrease pain perception via peripheral and central mechanisms. For peripheral mechanisms, the mediators that reduce hypersensitivity include proteases, kynurenic acid, and GABA ([@bib47]). Short-chain fatty acids regulate leucocyte functions, and one of these short-chain fatty acids, butyrate, reduces pain associated with nerve injury by inhibiting histone deacetylase ([@bib47]). Bile acids are another type of mediator, that may reduce pain by activating release of endogenous opioids from macrophages ([@bib47]). The bacteria that could be implicated in the production of the abovementioned mediators include *Lactobacillus rhamnosus* ([@bib125]; [@bib139]), *L. brevis* ([@bib12]), *L. buchneri* ([@bib26]), *L. paracasei* ([@bib78]), *L. plantarum* ([@bib139]), *L. delbruekii* subsp. *bulgaricus* ([@bib139]), *Monascus purpureus* ([@bib144]), *Streptococcus salivarius* subsp. *thermophilus* ([@bib166]), *Clostridium butyricum* ([@bib94]; [@bib128]), *Coprococcus eutactus* ([@bib128]), *C. comes* ([@bib128]), *Bifidobacterium* spp. ([@bib128]), *B. dentium* ([@bib12]; [@bib125]), *B. infantis* ([@bib12]), *B. adolescentis* ([@bib12]), *Bacteroides fragilis* ([@bib142]), *Parabacteroides* spp. ([@bib142]), *Faecalibacterium prausnitzii* ([@bib128]), *Eubacterium hallii* ([@bib128]), *E. rectale* ([@bib128]), *Anaerostripes butyraticus* ([@bib128]), *A. caccae* ([@bib128]), *A. hadrus* ([@bib128]), *Butyricicoccus pullicaecorum* ([@bib128]), *Roseburia faecis* ([@bib128]), *R. inulinivorans* ([@bib128]), *R. intestinalis* ([@bib128]), *R. hominis* ([@bib128]), and *Escherichia* spp. ([@bib142]), again supporting a potential association between gut microbiome and pain outcomes.

For central mechanisms, central sensitisation may be the result of glial activation which ultimately leads to decreased GABAergic synaptic neurotransmission and/or elevated glutamatergic synaptic neurotransmission, and the gut microbiome plays a role in microglial function, maturation and morphology ([@bib47]). There is however no direct evidence, to our knowledge, linking the gut microbiome to central sensitisation, although GABA-producing bacteria could theoretically be implicated.

In addition to the abovementioned mechanisms linking the human microbiome and pain outcomes, the human microbiome influences mental health outcomes. Probiotics (e.g. *Lactobacillus* spp., *Bacillus* spp., *Clostridium* spp., *Bifidobacterium* spp.) can reduce anxiety ([@bib96]) and depression ([@bib96]; [@bib154]), and gut microbiome regulation (e.g. probiotics, dietary changes) can reduce anxiety ([@bib167]). There is also an association between gut microbiome and sleep ([@bib140]). Experimental sleep deprivation has been shown to influence the gut microbiome ([@bib14]; [@bib126]), however to our knowledge no study has investigated whether changes to the microbiome influence sleep outcomes. By improving mental health and potentially sleep, due to the changes in gut microbiome, greenspace exposure may improve pain outcomes.

It has recently been demonstrated in a mouse study that a diverse gut microbiome is required for fear extinction learning to occur ([@bib27]), which may have implications for chronic pain. There is some evidence to suggest that people with chronic pain have reduced differential learning ([@bib52]), and that fear-avoidance beliefs ([@bib34]; [@bib57]; [@bib66]; [@bib112]) are associated with chronic pain. [@bib27] suggested that interventions to reduce fear-avoidance (e.g. graded exposure) may have had limited success in those with lower gut microbiome diversity. These findings may also have implications for changing other cognitive elements of the pain experience such as pain beliefs, and expectations regarding pain and recovery.

Although the association between environmental microbiome and pain outcomes has not been investigated, we suggest that such an association is likely to exist owing to the influence of environmental microbiomes on human microbiomes, and the existence of multiple potential pathways linking the human microbiome and pain outcomes.

4.2. Sights and sounds of nature {#sec4.2}
--------------------------------

The biophilia hypothesis -- where humans have an innate and natural affiliation with nature ([@bib161]) -- has traditionally been central to the proposed link between greenspace exposure and health outcomes, and relates to exposure to the sights and sounds of nature. Listening to pleasant nature sounds during elective Caesarean section has been shown to reduce post-operative pain severity ([@bib37]), and also resulted in lower pain for those undergoing mechanical ventilation ([@bib132]). Combined natural sounds and sights have resulted in lower pain severity compared with both city sounds and sights and with a control during bone marrow aspiration and biopsy ([@bib84]). [@bib158] demonstrated differences in the effect of viewing an array of natural scenery on experimental pain sensation. They found that the combined prospect/refuge scenery resulted in lower pain sensation than prospect, refuge and hazard scenery and the control (a black screen). Listening to pleasant nature sounds has also been reported to improve sleep ([@bib117]), while a virtual nature experience reduced stress ([@bib93]), which may also lead to a reduction in pain. Greenspace exposure could therefore result in a reduction in pain due to exposure to natural sights and sounds.

4.3. Phytoncides {#sec4.3}
----------------

The antimicrobial volatile organic compounds emitted as a defence mechanism by plants are called phytoncides, and they permeate the air particularly in or near greenspace ([@bib39]). To our knowledge no study has investigated the relationship between phytoncides and pain in humans, however an analgesic effect has been reported for mice ([@bib25]).

Given their antimicrobial properties ([@bib39]), phytoncides may also influence the microbiome. To our knowledge, the impact of phytoncide exposure on the microbiome has not been examined, however the effect of dietary phytoncide supplements on gut *Lactobacillus* spp. and *Escherichia coli* counts has ([@bib75]; [@bib90]; [@bib171]). These studies of livestock found that dietary phytoncides supplements gave mixed results, with one study reporting no change ([@bib172]), and others reporting significantly higher *Lactobacillus* spp. counts ([@bib75]; [@bib90]; [@bib171]) and lower *Escherichia coli* counts ([@bib75]; [@bib90]) with the supplements. These alternations to the gut microbiome may influence pain perception, due to the mechanisms outlined above.

Phytoncides may also influence the human immune system, particularly natural killer cell function. In vitro studies have shown that phytoncides can enhance human natural killer cell function ([@bib88]). Natural killer cell function was enhanced for people walking in forests, but not in cities, and importantly phytoncides were only detected in the forest and not in the city ([@bib89]). This study did not, however, account for the potential impact of other forest exposures (e.g. environmental microbiome) that may have influenced the relationship. Nonetheless, greenspace exposure appears to improve natural killer cell activity, and natural killer cells have recently been proposed as a treatment for some types of pain ([@bib32]).

Phytoncides have also been shown to improve sleep and reduce anxiety in animal studies ([@bib25]), providing further evidence of a potential link between greenspace exposure, phytoncides, and pain outcomes. Different anxiety responses have been observed with exposure to different tree species in forest bathing ([@bib45]), which could be explained by differences in the phytoncides released. A recent randomised crossover study ([@bib56]) compared two forest bathing exposures; one where participants could see the forest and the other where they could not. There was a significant reduction in trait-anxiety, depression, confusion and fatigue when the forest could be viewed, but not when the view was occluded; however there were no significant differences in the outcomes between the two exposures post-exposure ([@bib56]). [@bib56] indicated that phytoncides are unlikely to be the sole reason for changes in human health outcomes related to greenspace exposure, but supported the notion that greenspace exposure may improve pain outcomes.

4.4. Negative air ions {#sec4.4}
----------------------

Negative air ions are generated by plants (see [@bib68] for a list), shear forces of water, sunlight, atmospheric radiant or cosmic rays, and natural and artificial corona discharge ([@bib68]). They are less prevalent in urban settings compared with forests, places with moving water, and mountainous areas ([@bib104]). There is some, albeit limited, evidence of negative air ion exposure altering pain outcomes ([@bib31]; [@bib109]; [@bib122]), through a range of potential effects on humans and other animals. These effects include decreased cyclic nucleotides, lower dopamine, activation of natural killer cells, and improved mental health ([@bib68]), all of which may reduce pain, including chronic pain ([@bib32]; [@bib34]; [@bib57]; [@bib66]; [@bib91]; [@bib95]; [@bib147]).

Negative air ions have also been shown to kill or reduce a range of microbes, including *Serratia marcescens, Staphylococcus albus, S. aureus, S. epidermidis, Pseudomonas veronii, P. fluorescens, Salmonella Enteriditis, Candida albicans, Escherichia coli,* and *Penicillum notatum*, and have been shown to prevent *Acinetobacter* infections ([@bib68]). These antimicrobial effects indicate that negative air ions have the potential to alter the human microbiome, which may therefore influence pain outcomes.

4.5. Sunlight exposure {#sec4.5}
----------------------

Sunlight exposure is the first of three generic factors that we propose may link greenspace exposure to pain outcomes. Depending on the weather, geographic location, canopy cover and time of day, spending time in greenspace is likely to lead to sunlight exposure. Sunlight exposure is perhaps most commonly associated with vitamin D production, but exposure to sunlight also leads to the production of beta-endorphin (an endogenous opioid peptide), melatonin, and nitric oxide (a vasodilator), as well as the release of carbon monoxide from haemoglobin (a vasodilator), and expression of the proopiomelanocortin gene (which results in the production of beta-endorphin and cortisol) ([@bib54]).

Observational studies have identified an association between vitamin D levels and arthritis, muscle pain, chronic widespread pain ([@bib163]), and low back pain ([@bib169]); however, studies investigating the impact of vitamin D supplementation on pain outcomes have generally shown that vitamin D supplementation is no better than placebo for people with lower back pain ([@bib170]) and non-specific musculoskeletal disorders ([@bib42]). However, there is some evidence of vitamin D lowering pain intensity for those with chronic widespread pain ([@bib168]). The discrepancy between the observational and experimental evidence regarding the relationship vitamin D and pain may be the result of vitamin D acting as a proxy-measure of sunlight exposure. Sunlight exposure could lead to a change in pain through non-vitamin D pathways, including the release of beta-endorphins ([@bib54]) and melatonin ([@bib174]), or indeed changes in the microbiome ([@bib160]). Furthermore, sunlight exposure ([@bib35]) and vitamin D supplementation ([@bib65]) have led to improved sleep including for people with chronic pain specifically ([@bib58]). Vitamin D supplementation has also resulted in reduced inflammation and improvements in depression ([@bib65]), which may in turn contribute to improved pain outcomes.

4.6. Physical activity {#sec4.6}
----------------------

Exposure to greenspace reportedly facilitates physical activity ([@bib72]); the second generic factor in our review. Physical activity is commonly prescribed by health professionals, particularly for patients in pain. Evidence in support of physical activity for reducing the prevalence and impact of pain include findings of physical activity being associated with a lower incidence of neck pain ([@bib76]), and lower prevalence of lower back pain ([@bib5]), including frequent and chronic lower back pain ([@bib136]). Furthermore, interventions to increase incidental physical activity lead to improved lower back pain-related disability ([@bib4]). For those with musculoskeletal conditions in particular, physical activity may decrease nociception by improving the underlying musculoskeletal condition. Exercise reduces inflammation ([@bib141]; [@bib173]) and stress ([@bib16]; [@bib130]), improves sleep ([@bib11]; [@bib80]; [@bib85]; [@bib99]; [@bib143]) and mental health ([@bib13]; [@bib106]; [@bib111]; [@bib116]; [@bib130]), and changes the human microbiome ([@bib102]). The health improvements associated with exercise may also influence pain perception and the risk of transitioning from acute to chronic pain. Thus, physical activity, particularly when facilitated by greenspace exposure, is likely to also contribute to a reduction in the global burden of pain.

4.7. Social integration {#sec4.7}
-----------------------

Although social integration is not specific to greenspace, greenspace exposure is associated with a range of social benefits and has been identified as a facilitator of social integration and cohesion ([@bib67]), and would therefore be expected to improve social support. Social support has been associated with pain perception ([@bib23]), including experimental pain ([@bib22]), while low levels of social support are associated with a higher risk of transitioning from acute to chronic pain ([@bib40]). In addition, higher levels of social support and integration are associated with lower levels of inflammation ([@bib153]), better sleep ([@bib71]), and better mental health ([@bib149]) which may all in turn influence pain perception. Of note, sleep may also influence the gut microbiome ([@bib14]; [@bib126]) and thus potentially pain perception through that mechanism as well. We therefore suggest that greenspace exposure is likely to decrease both pain perception, and the transition from acute to chronic pain, via improvements in social integration and support.

5. Recommendations {#sec5}
==================

Here we argue that exposure to greenspace may be an effective, safe and accessible strategy to help alleviate the global burden of pain. With the exception of those with compromised immune systems, exposure to greenspace should therefore be encouraged for those experiencing pain.

The association and potential therapeutic benefit of greenspace exposure for those with pain should be further explored, with a particular focus on the transition from acute to chronic pain, and the prevalence and burden of chronic pain. To do this we need valid and reliable measures of exposure to greenspace (e.g. time spent in greenspace, characteristics of the greenspace), which, to our knowledge, do not currently exist.

One of the advantages of greenspace exposure as an intervention for pain, particularly chronic pain, is that it is not reliant on medical intervention, and could be implemented while on waiting lists for specialist appointments -- a particularly important consideration in the socially isolating conditions of a pandemic, with elective surgery and pain clinics closed down. It can take years for patients to gain access to these services ([@bib6]), during which time their nervous systems change and the burden of their pain increases. The caveat to this is, however, that appropriate greenspaces must be accessible to those who require them. Several general barriers to such greenspace access have been suggested, and include a lack of amenities ([@bib29]; [@bib134]), safety concerns ([@bib18]; [@bib29]; [@bib134]; [@bib135]), proximity to greenspace ([@bib135]), and issues with transport ([@bib18]; [@bib29]; [@bib41]; [@bib134]). Perhaps more importantly, a lack of interest ([@bib18]; [@bib41]) and time ([@bib18]; [@bib41]; [@bib55]; [@bib135]), and debilitating health conditions ([@bib18]; [@bib29]; [@bib41]; [@bib134]) have also been identified as barriers. Finally, in the current coronavirus pandemic situation, strict lockdowns in countries like Italy are likely to reduce greenspace exposure for many people. These barriers support the need to optimise opportunistic encounters with greenspace, such as advice to optimise private greenspaces to maximize benefits, as well as utilising verges and high-use areas (e.g. commuter paths, work place environments) for optimal greenspace, so that passive exposure to the aerobiome is achieved. Stakeholder engagement is also essential to improve usage of public greenspaces ([@bib129]).

To optimise greenspaces to improve pain outcomes we need to understand which elements of greenspace have the most influence on pain outcomes (e.g. phytoncides, microbiome), what the most advantageous greenspaces comprise of (e.g. the specific microbes that should be in relative abundance), and how to encourage people, particularly those in pain, into such greenspaces.

With specific reference to the environmental microbiome, further work is required to characterise the components of the environmental microbiome that directly influence pain. Such health outcome-environmental microbiome association studies have begun in non-pain related areas (e.g. anxiety-like behaviour ([@bib92])), and are a required precursor to not only understanding the level of exposure to these potentially pain-mitigating microbiota from greenspaces, but also how to derive these pain management benefits via targeted changes to greenspaces.

6. Conclusions {#sec6}
==============

Here we articulate how and why exposure to greenspaces is likely to reduce pain, particularly chronic pain. Greenspaces provide exposure to environmental microbiomes, phytoncides, negative air ions, natural sights and sounds, and sunlight, and may facilitate physical activity and social integration. We describe established or potential links between these specific exposures and pain outcomes. Further research is required to determine the mechanistic pathways that link greenspace and pain outcomes, as well as the nature and duration of specific exposures relevant to optimising pain outcomes. By making available public and private greenspaces accordingly, and reducing barriers to access, we are likely to see a reduction in the global burden of pain.
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